A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's Disease-Reference-Cited by-同舟云学术

A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's Disease

Published:2024-01-22 Issue: Volume: Page:
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Weiss Alexandra¹,Barnes Edward L.²³⁴,Bewtra Meenakshi¹⁵

Affiliation:

1. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA;

2. Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA;

3. University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA;

4. Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina, Chapel Hill, North Carolina, USA;

5. Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference12 articles.

1. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials;Danese;Lancet,2022

2. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment;Loftus;Clin Gastroenterol Hepatol,2023

3. Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active ulcerative colitis;Gastroenterol Hepatol (NY),2022

4. OP33. Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe ulcerative colitis (UC): Results from the UPA phase 3 programme;Colombel;J Crohns Colitis,2022

5. Upadacitinib induction and maintenance therapy for Crohn's disease;Loftus;N Engl J Med,2023